TrovaGene, Inc. (TROV) belonging to the Medical sector has declined -25.71% and closed its last trading session at $1.3.
The company reported its EPS on 03/15/2017. Currently, the stock has a 1 Year Price Target of $6.23.
The consensus recommendation, according to Zacks Investment research, is 1.67. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1.67 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.67 and 1.67 respectively.
TrovaGene, Inc. on 03/15/2017 reported its EPS as $-0.25 with the analysts projecting the EPS of the stock as $-0.32. The company beat the analyst EPS Estimate with the difference of $0.07. This shows a surprise factor of 21.9%.
Many analysts have provided their estimated foresights on TrovaGene, Inc. Earnings, with 3 analysts believing the company would generate an Average Estimate of $-0.28.
Whereas they predicted High and Low Earnings Estimate as $-0.28 and $-0.29 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.35.
Analysts are also projecting an Average Revenue Estimate for TrovaGene, Inc. as $480 Million in the Current Quarter. This estimate is provided by 3 analysts.
The High Revenue estimate is predicted as 540 Million, while the Low Revenue Estimate prediction stands at 380 Million. The company’s last year sales total was 120 Million.
For the Current Quarter, the growth estimate for TrovaGene, Inc. is 20%, while for the Next Quarter the stock growth estimate is 17.6%.
The Company got Downgrade by Maxim Group on 16-Mar-17 from Buy to Hold.
Insider Trades for TrovaGene, Inc. show that the latest trade was made on 1 Jan 2017 where Erlander (Mark), the Officer completed a transaction type “Buy” in which 50000 shares were traded at a price of $0.
Over the period of 6 months, Insider Purchases show a total of 5 transaction in which 485000 shares were traded.
3 analysts projected Price Targets for TrovaGene, Inc.. The analysts believe that the company stock price could grow as high as $9. The Low Price target projection by analysts is $1.7 and the Mean Price Target is $6.23.
TrovaGene, Inc. (TROV) has the market capitalization of $39.44 Million. The company rocked its 52-Week High of $6.67 on Apr 19, 2016 and touched its 52-Week Low of $1.25 on Mar 16, 2017.
The stock has Return on Assets (ROA) of -61.6 percent. Return on Equity (ROE) stands at -102% and Return on Investment (ROI) of -38.8 percent.
The stock is currently showing YTD performance of -38.1 Percent. The company has Beta Value of 0.72 and ATR value of 0.15. The Weekly and Monthly Volatility stands at 12.37% and 6.90%.